Holen Sie sich die Stockscreener-App
23.63
0.13%
-0.03
Handel nachbörslich:
23.09
-0.54
-2.29%
Schlusskurs vom Vortag:
$23.66
Offen:
$23.74
24-Stunden-Volumen:
1.31M
Relative Volume:
1.31
Marktkapitalisierung:
$1.93B
Einnahmen:
$305.00K
Nettoeinkommen (Verlust:
$-328.98M
KGV:
-5.5402
EPS:
-4.2652
Netto-Cashflow:
$-309.60M
1W Leistung:
+6.63%
1M Leistung:
+9.50%
6M Leistung:
+74.39%
1J Leistung:
+9.55%
1-Tages-Spanne:
$23.35
$24.05
1-Wochen-Bereich:
$22.11
$24.23
52-Wochen-Spanne:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
23.63 | 2.20B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Trend analysis for Viridian Therapeutics Inc. this weekQuarterly Risk Review & High Win Rate Trade Alerts - newser.com
Smart tools for monitoring Viridian Therapeutics Inc.’s price actionJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - newser.com
Can Viridian Therapeutics Inc. stock attract ESG capital inflowsMarket Rally & Scalable Portfolio Growth Methods - newser.com
Top chart patterns to watch in Viridian Therapeutics Inc.Bull Run & Weekly High Momentum Picks - newser.com
How hedge fund analytics apply to Viridian Therapeutics Inc. stockTrade Exit Report & Comprehensive Market Scan Insights - newser.com
Why Viridian Therapeutics Inc. (1S1) stock is a must watch tickerWeekly Stock Analysis & Verified Chart Pattern Signals - newser.com
Regression analysis insights on Viridian Therapeutics Inc. performanceDay Trade & Free Verified High Yield Trade Plans - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsSell Signal & Community Consensus Trade Alerts - newser.com
Chart based analysis of Viridian Therapeutics Inc. trendsJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
Can swing trading help recover from Viridian Therapeutics Inc. lossesMarket Rally & Advanced Technical Signal Analysis - newser.com
Oppenheimer Maintains Viridian Therapeutics (VRDN) Outperform Recommendation - MSN
How Viridian Therapeutics Inc. stock reacts to job market dataEarnings Growth Summary & Free Community Supported Trade Ideas - newser.com
Will Viridian Therapeutics Inc. (1S1) stock attract long term capital inflowsCPI Data & Accurate Entry and Exit Point Alerts - newser.com
Moody Aldrich Partners LLC Has $1.25 Million Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Reassessing Viridian Therapeutics (VRDN) Valuation Following Insider Buying and Progress in Thyroid Eye Disease Program - Sahm
Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors - Barron's
Fairmount Funds Management LLC's Strategic Acquisition in Viridi - GuruFocus
Wedbush Reduces Earnings Estimates for Viridian Therapeutics - MarketBeat
Can machine learning forecast Viridian Therapeutics Inc. recoveryGold Moves & Fast Entry Momentum Trade Alerts - newser.com
How supply chain issues affect Viridian Therapeutics Inc. stock2025 Top Decliners & Free High Return Stock Watch Alerts - newser.com
How Viridian Therapeutics Inc. stock performs in interest rate cyclesEarnings Miss & Consistent Growth Stock Picks - newser.com
Is Viridian Therapeutics Inc. (1S1) stock a buy on weaknessTrade Volume Report & Real-Time Volume Surge Alerts - newser.com
Using Ichimoku Cloud for Viridian Therapeutics Inc. technicalsEarnings Overview Report & Short-Term High Return Ideas - newser.com
How buybacks impact Viridian Therapeutics Inc. stock value2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
Wedbush Expects Reduced Earnings for Viridian Therapeutics - MarketBeat
Can Viridian Therapeutics Inc. (1S1) stock survive global slowdownWeekly Trend Report & Fast Moving Market Watchlists - newser.com
Published on: 2025-10-30 01:27:01 - newser.com
Published on: 2025-10-29 21:18:30 - newser.com
Is Viridian Therapeutics Inc. stock attractive for ETFsOptions Play & Weekly Setup with ROI Potential - Fundação Cultural do Pará
Is Viridian Therapeutics Inc. stock a smart buy before Fed meetingQuarterly Profit Review & Daily Growth Stock Investment Tips - newser.com
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):